{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:22:42Z","timestamp":1789392162165,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10549-025-07836-x","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T15:29:50Z","timestamp":1765553390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of abemaciclib plus endocrine therapy versus endocrine therapy alone in HR\u2009+\u2009and HER2-negative breast cancer; a systematic review and meta-analysis"],"prefix":"10.1007","volume":"215","author":[{"given":"Khudija","family":"Sadia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazmeen","family":"Talia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishtiaq","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhal","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Khubaib","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Faizan","family":"Kamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajra Zainab","family":"Chaudry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiba","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamna Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Ejaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Ubaid","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahmeera","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-4042","authenticated-orcid":false,"given":"Muhammad","family":"Abdul Qadeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"issue":"7","key":"7836_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ (2021) Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 134(7):783\u2013791","journal-title":"Chin Med J (Engl)"},{"issue":"3","key":"7836_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020 GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"7836_CR3","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s40265-019-01208-8","volume":"79","author":"V Aggelis","year":"2019","unstructured":"Aggelis V, Johnston SRD (2019) Advances in endocrine-based therapies for estrogen receptor-positive metastatic breast cancer. Drugs 79(17):1849\u20131866","journal-title":"Drugs"},{"issue":"7","key":"7836_CR4","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/jcm13071873","volume":"13","author":"C Tommasi","year":"2024","unstructured":"Tommasi C, Air\u00f2 G, Prattic\u00f2 F et al (2024) Hormone receptor-positive\/HER2-positive breast cancer: hormone therapy and anti-HER2 treatment: an update on treatment strategies. J Clin Med 13(7):1873","journal-title":"J Clin Med"},{"issue":"11","key":"7836_CR5","first-page":"2315","volume":"12","author":"L Altucci","year":"1996","unstructured":"Altucci L, Addeo R, Cicatiello L et al (1996) 17beta-estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12(11):2315\u20132324","journal-title":"Oncogene"},{"issue":"3","key":"7836_CR6","first-page":"2077","volume":"14","author":"M Meyerson","year":"1994","unstructured":"Meyerson M, Harlow E (1994) Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14(3):2077\u20132086","journal-title":"Mol Cell Biol"},{"issue":"8","key":"7836_CR7","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","volume":"29","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, Andr\u00e9 F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cort\u00e9s J, Curigliano G, Di\u00e9ras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP (2018) 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)\u2020. Ann Oncol 29(8):1634\u20131657. https:\/\/doi.org\/10.1093\/annonc\/mdy192","journal-title":"Ann Oncol"},{"issue":"4","key":"7836_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.21037\/atm-21-5110","volume":"10","author":"L Zhu","year":"2022","unstructured":"Zhu L, Wang M, Luo X et al (2022) Pharmacoeconomic evaluations of CDK4\/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review. Ann Transl Med 10(4):233","journal-title":"Ann Transl Med"},{"key":"7836_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","volume":"62","author":"CK Osborne","year":"2011","unstructured":"Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233\u2013247","journal-title":"Annu Rev Med"},{"issue":"7","key":"7836_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1517\/13543784.2013.798641","volume":"22","author":"AA Abate","year":"2013","unstructured":"Abate AA, Pentimalli F, Esposito L, Giordano A (2013) ATP-noncompetitive CDK inhibitors for cancer therapy: an overview. Expert Opin Investig Drugs 22(7):895\u2013906","journal-title":"Expert Opin Investig Drugs"},{"issue":"13","key":"7836_CR11","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1038\/sj.onc.1209987","volume":"26","author":"L Bagella","year":"2007","unstructured":"Bagella L, Sun A, Tonini T et al (2007) A small molecule based on the pRb2\/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo. Oncogene 26(13):1829\u20131839","journal-title":"Oncogene"},{"issue":"18","key":"7836_CR12","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738\u20131748","journal-title":"N Engl J Med"},{"issue":"30","key":"7836_CR13","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.2174\/13816128113199990377","volume":"19","author":"L Esposito","year":"2013","unstructured":"Esposito L, Indovina P, Magnotti F, Conti D, Giordano A (2013) Anticancer therapeutic strategies based on CDK inhibitors. Curr Pharm Des 19(30):5327\u20135332","journal-title":"Curr Pharm Des"},{"issue":"2","key":"7836_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/sj.cdd.4400323","volume":"5","author":"MM Kasten","year":"1998","unstructured":"Kasten MM, Giordano A (1998) pRb and the cdks in apoptosis and the cell cycle. Cell Death Differ 5(2):132\u2013140","journal-title":"Cell Death Differ"},{"issue":"7","key":"7836_CR15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8(7):547\u2013566","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"7836_CR16","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1053\/j.seminoncol.2018.01.006","volume":"44","author":"SC Scott","year":"2017","unstructured":"Scott SC, Lee SS, Abraham J (2017) Mechanisms of therapeutic CDK4\/6 inhibition in breast cancer. Semin Oncol 44(6):385\u2013394","journal-title":"Semin Oncol"},{"issue":"6","key":"7836_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","volume":"50","author":"D Wekking","year":"2023","unstructured":"Wekking D, Lambertini M, Dess\u00ec M et al (2023) CDK4\/6 inhibitors in the treatment of metastatic breast cancer: focus on toxicity and safety. Semin Oncol 50(6):131\u2013139","journal-title":"Semin Oncol"},{"issue":"1","key":"7836_CR18","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr","year":"2020","unstructured":"Sledge GW Jr, Toi M, Neven P et al (2020) The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 6(1):116\u2013124","journal-title":"JAMA Oncol"},{"issue":"8","key":"7836_CR19","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","volume":"35","author":"MP Goetz","year":"2024","unstructured":"Goetz MP, Toi M, Huober J, Sohn J, Tr\u00e9dan O, Park IH, Campone M, Chen SC, Manso LM, Paluch-Shimon S, Freedman OC, O\u2019Shaughnessy J, Pivot X, Tolaney SM, Hurvitz SA, Llombart-Cussac A, Andr\u00e9 V, Saha A, van Hal G, Shahir A, Iwata H, Johnston SRD (2024) Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 35(8):718\u2013727. https:\/\/doi.org\/10.1016\/j.annonc.2024.04.013","journal-title":"Ann Oncol"},{"key":"7836_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"issue":"1","key":"7836_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210","journal-title":"Syst Rev"},{"issue":"366","key":"7836_CR22","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) Rob 2: a revised tool for assessing the risk of bias in randomized trials. BMJ 28(366):l4898","journal-title":"BMJ"},{"issue":"7414","key":"7836_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"12","key":"7836_CR24","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/CM9.0000000000003151","volume":"138","author":"X Hu","year":"2025","unstructured":"Hu X, Zhang Q, Sun T, Yin Y, Li H, Yan M, Tong Z, Li M, Teng Y, Oppermann CP, Kanakasetty GB, Portugal MAC, Yang L, Zhang W, Jiang Z (2025) Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+\/HER2- advanced breast cancer: final results of the randomized phase III MONARCH plus trial. Chin Med J (Engl) 138(12):1477\u20131486. https:\/\/doi.org\/10.1097\/CM9.0000000000003151","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"7836_CR25","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s12282-021-01239-8","volume":"28","author":"K Inoue","year":"2021","unstructured":"Inoue K, Masuda N, Iwata H et al (2021) Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy. Breast Cancer 28(5):1038\u20131050","journal-title":"Breast Cancer"},{"issue":"35","key":"7836_CR26","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1200\/JCO.23.02733","volume":"42","author":"KL Jhaveri","year":"2024","unstructured":"Jhaveri KL, Lim E, Jeselsohn R et al (2024) Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and in combination with targeted therapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: phase Ia\/Ib EMBER. J Clin Oncol 42(35):4173\u20134186","journal-title":"J Clin Oncol"},{"issue":"12","key":"7836_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","volume":"392","author":"KL Jhaveri","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML, Kim S-B, Tokunaga E, Aftimos P, Saura C, O\u2019Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, Garc\u00eda Tinoco MdlL, Sohn J, Mattar A, Zhang Q, Huang C-S, Hung C-C, Martinez Rodriguez JL, Ru\u00edz Borrego M, Nakamura R, Pradhan KR, von Cramer Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard F-C (2025) Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 392(12):1189\u20131202. https:\/\/doi.org\/10.1056\/NEJMoa2410858","journal-title":"N Engl J Med"},{"issue":"1","key":"7836_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im S-A, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5(1):5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"issue":"9","key":"7836_CR29","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"P Rastogi","year":"2024","unstructured":"Rastogi P, O\u2019Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang C-S, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Andr\u00e9 V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S (2024) Adjuvant abemaciclib plus endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. J Clin Oncol 42(9):987\u2013993. https:\/\/doi.org\/10.1200\/JCO.23.01994","journal-title":"J Clin Oncol"},{"issue":"25","key":"7836_CR30","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35(25):2875\u20132884. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585","journal-title":"J Clin Oncol"},{"issue":"1","key":"7836_CR31","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s12282-021-01295-0","volume":"29","author":"M Takahashi","year":"2022","unstructured":"Takahashi M, Tokunaga E, Mori J et al (2022) Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Breast Cancer 29(1):174\u2013184","journal-title":"Breast Cancer"},{"issue":"1","key":"7836_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/cas.15600","volume":"114","author":"M Toi","year":"2023","unstructured":"Toi M, Huang CS, Im YH, Sohn J, Zhang W, Sakaguchi S, Haddad N, van Hal G, Sledge GW (2023) Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: overall survival from MONARCH 2. Cancer Sci 114(1):221\u2013226. https:\/\/doi.org\/10.1111\/cas.15600","journal-title":"Cancer Sci"},{"key":"7836_CR33","doi-asserted-by":"publisher","first-page":"113555","DOI":"10.1016\/j.ejca.2024.113555","volume":"199","author":"SM Tolaney","year":"2024","unstructured":"Tolaney SM, Guarneri V, Seo JH, Cruz J, Abreu MH, Takahashi M, Barrios C, McIntyre K, Wei R, Munoz M, Antonio BS, Liepa AM, Martin M, Johnston SRD, Kellokumpu-Lehtinen P-L, Harbeck N (2024) Long-term patient-reported outcomes from monarchE: abemaciclib plus endocrine therapy as adjuvant therapy for HR+, HER2-, node-positive, high-risk, early breast cancer. Eur J Cancer 199:113555. https:\/\/doi.org\/10.1016\/j.ejca.2024.113555","journal-title":"Eur J Cancer"},{"key":"7836_CR34","doi-asserted-by":"publisher","first-page":"175883592412867","DOI":"10.1177\/17588359241286775","volume":"16","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Shen K, Song CG et al (2024) Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study. Ther Adv Med Oncol 16:17588359241286776","journal-title":"Ther Adv Med Oncol"},{"key":"7836_CR35","doi-asserted-by":"publisher","first-page":"175883592096392","DOI":"10.1177\/1758835920963925","volume":"12","author":"QY Zhang","year":"2020","unstructured":"Zhang QY, Sun T, Yin YM et al (2020) MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol 12:1758835920963925","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"7836_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/COC.0000000000001143","volume":"48","author":"Z Qureshi","year":"2025","unstructured":"Qureshi Z, Jamil A, Fatima E, Altaf F, Siddique R (2025) Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+\/HER2- advanced or metastatic breast cancer: a systematic review and meta-analysis. Am J Clin Oncol 48(1):6\u201315","journal-title":"Am J Clin Oncol"},{"issue":"23","key":"7836_CR37","first-page":"7252","volume":"25","author":"Q Tian","year":"2021","unstructured":"Tian Q, Gao H, Zhou Y, Yang J (2021) Overall survival and progression-free survival with cyclin-dependent kinase 4\/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials. Eur Rev Med Pharmacol Sci 25(23):7252\u20137267","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"7836_CR38","first-page":"101824","volume":"56","author":"L Mastrantoni","year":"2023","unstructured":"Mastrantoni L, Orlandi A, Palazzo A et al (2023) The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4\/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis. Eclin Med 56:101824","journal-title":"Eclin Med"},{"issue":"2","key":"7836_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/0284186X.2018.1532603","volume":"58","author":"TM B\u00f8ttcher","year":"2019","unstructured":"B\u00f8ttcher TM, Cold S, Jensen AB (2019) Treatment of advanced HR+\/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib. Acta Oncol 58(2):147\u2013153","journal-title":"Acta Oncol"},{"issue":"1","key":"7836_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-018-4901-0","volume":"172","author":"C Messina","year":"2018","unstructured":"Messina C, Cattrini C, Buzzatti G et al (2018) CDK4\/6 inhibitors in advanced hormone receptor-positive\/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 172(1):9\u201321","journal-title":"Breast Cancer Res Treat"},{"key":"7836_CR41","doi-asserted-by":"publisher","first-page":"891580","DOI":"10.3389\/fonc.2022.891580","volume":"12","author":"GL Rampioni Vinciguerra","year":"2022","unstructured":"Rampioni Vinciguerra GL, Sonego M, Segatto I, Dall\u2019Acqua A, Vecchione A, Baldassarre G, Belletti B (2022) CDK4\/6 inhibitors in combination therapies: better in company than alone: a mini review. Front Oncol 12:891580. https:\/\/doi.org\/10.3389\/fonc.2022.891580","journal-title":"Front Oncol"},{"issue":"1","key":"7836_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5603\/EP.a2023.0007","volume":"74","author":"T Huang","year":"2023","unstructured":"Huang T, He Y, Yu C, Mao F, Si Y (2023) The effect and safety of CDK4\/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials. Endokrynol Pol 74(1):89\u2013105","journal-title":"Endokrynol Pol"},{"issue":"7","key":"7836_CR43","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/onco.13806","volume":"26","author":"S Badaoui","year":"2021","unstructured":"Badaoui S, Kichenadasse G, Rowland A, Sorich MJ, Hopkins AM (2021) Patient-reported outcomes predict progression-free survival of patients with advanced breast cancer treated with abemaciclib. Oncologist 26(7):562\u2013568","journal-title":"Oncologist"},{"issue":"6","key":"7836_CR44","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(20)30112-1","volume":"21","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Wardley AM, Zambelli S et al (2021) Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol 21(6):763\u2013775","journal-title":"Lancet Oncol"},{"key":"7836_CR45","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/DDDT.S137783","volume":"12","author":"SP Corona","year":"2018","unstructured":"Corona SP, Generali D (2018) Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HER2- advanced breast cancer. Drug Des Devel Ther 12:321\u2013330","journal-title":"Drug Des Devel Ther"},{"issue":"17","key":"7836_CR46","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.3390\/ijms21176400","volume":"21","author":"M Piezzo","year":"2020","unstructured":"Piezzo M, Chiodini P, Riemma M, Cocco S, Caputo R, Cianniello D, Di Gioia G, Di Lauro V, Rella FD, Fusco G, Iodice G, Nuzzo F, Pacilio C, Pensabene M, De Laurentiis M (2020) Progression-free survival and overall survival of CDK 4\/6 inhibitors plus endocrine therapy in metastatic breast cancer: a systematic review and meta-analysis. Int J Mol Sci 21(17):6400. https:\/\/doi.org\/10.3390\/ijms21176400","journal-title":"Int J Mol Sci"},{"issue":"1","key":"7836_CR47","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1186\/s12885-023-11322-2","volume":"23","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wu J, Ji Z et al (2023) Comparative efficacy and safety of different combinations of three CDK4\/6 inhibitors with endocrine therapies in HR+\/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis. BMC Cancer 23(1):816","journal-title":"BMC Cancer"},{"issue":"21","key":"7836_CR48","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.3390\/cancers14215388","volume":"14","author":"M Abdelmalak","year":"2022","unstructured":"Abdelmalak M, Singh R, Anwer M, Ivanchenko P, Randhawa A, Ahmed M, Ashton AW, Du Y, Jiao X, Pestell R (2022) The renaissance of CDK inhibitors in breast cancer therapy: an update on clinical trials and therapy resistance. Cancers (Basel) 14(21):5388. https:\/\/doi.org\/10.3390\/cancers14215388","journal-title":"Cancers (Basel)"},{"issue":"1","key":"7836_CR49","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41523-023-00578-3","volume":"9","author":"J Ma","year":"2023","unstructured":"Ma J, Chan JJ, Toh CH, Yap YS (2023) Emerging systemic therapy options beyond CDK4\/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. NPJ Breast Cancer 9(1):74","journal-title":"NPJ Breast Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07836-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07836-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:39:11Z","timestamp":1767789551000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07836-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7836"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07836-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Not Applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}],"article-number":"39"}}